Oncolytics Biotech Inc.

NasdaqCM:ONCY Stock Report

Market Cap: US$105.9m

Oncolytics Biotech Past Earnings Performance

Past criteria checks 0/6

Oncolytics Biotech's earnings have been declining at an average annual rate of -5.4%, while the Biotechs industry saw earnings growing at 36.2% annually.

Key information

-5.41%

Earnings growth rate

10.77%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Seeking Alpha • Apr 25

Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths

Summary Oncolytics is narrowing Pelareorep development toward anal cancer and metastatic colorectal cancer, making its bull case more concrete. Pelareorep may turn “cold” tumors “hot,” potentially improving chemotherapy and checkpoint inhibitor responses across GI cancers. CRC data showed an unusually high 33% ORR versus 6%-11% historical SoC. This is why it received the FDA’s Fast Track designation. SCAC data showed encouraging response rates and complete responses. ONCY scheduled discussions with the FDA for a single-arm registrational pathway. I reckon ONCY’s dilution and clinical trial risks remain significant. Yet, the upcoming ER updates could help reframe ONCY around clearer regulatory timelines. Read the full article on Seeking Alpha
Analysis Article • Sep 03

Is Oncolytics Biotech (NASDAQ:ONCY) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Mar 11

Oncolytics Biotech: Continuing To Justify The Negativity

Summary Oncolytics Biotech's main asset, pelareorep, shows mixed results in trials, with no definitive efficacy signals and ongoing financial struggles threatening operations. The GOBLET trial in pancreatic cancer continues, but key data readouts are not expected until late 2025, adding uncertainty. ONCY's financial situation is dire, with cash runway only into Q3 2025, raising serious concerns about their ability to fund operations. Given the high risk, low market cap, and lack of clear efficacy, I maintain a "Sell" rating and advise against investing in ONCY. Read the full article on Seeking Alpha

Revenue & Expenses Breakdown

How Oncolytics Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:ONCY Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 260-331815
31 Dec 250-291513
30 Sep 250-251214
30 Jun 250-22913
31 Mar 250-231014
31 Dec 240-231015
30 Sep 240-201016
30 Jun 240-201215
31 Mar 240-211215
31 Dec 230-211213
30 Sep 230-241113
30 Jun 230-201012
31 Mar 230-18911
31 Dec 220-18811
30 Sep 220-17810
30 Jun 220-19915
31 Mar 220-211011
31 Dec 210-211110
30 Sep 210-221111
30 Jun 210-24116
31 Mar 210-231010
31 Dec 200-181010
30 Sep 200-2499
30 Jun 200-2297
31 Mar 200-2087
31 Dec 190-2678
30 Sep 190-1468
30 Jun 190-1468
31 Mar 190-1357
31 Dec 180-1257
30 Sep 180-1357
30 Jun 180-1356
31 Mar 180-1357
31 Dec 170-1257
30 Sep 170-1357
30 Jun 170-1347
31 Mar 170-1146
31 Dec 160-1146
30 Sep 160-1046
30 Jun 160-1046
31 Mar 160-1147
31 Dec 150-1046

Quality Earnings: ONCY is currently unprofitable.

Growing Profit Margin: ONCY is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ONCY is unprofitable, and losses have increased over the past 5 years at a rate of 5.4% per year.

Accelerating Growth: Unable to compare ONCY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ONCY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).

Return on Equity

High ROE: ONCY's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/12 17:41
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oncolytics Biotech Inc. is covered by 20 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas LoeCantor Fitzgerald Canada Corporation
Wang ChongEdison Investment Research
Patrick TrucchioH.C. Wainwright & Co.